50
Participants
Start Date
March 7, 2019
Primary Completion Date
February 28, 2023
Study Completion Date
December 30, 2024
Durvalumab / Tremelimumab Combination Therapy
"Starting dose:~durvalumab: 20mg/kg tremelimumab: 1mg/kg at cycles 2 to 5 only co-administered with durvalumab. The Recommended Phase 2 dose will be used for the dose expansion phase."
Research Site, Torino
Research Site, New Hyde Park
Research Site, Marseille
Research Site, Genova
Research Site, Milan
Research Site, Baltimore
Research Site, Madrid
Research Site, Charleston
Research Site, Cologne
Research Site, Lille
Research Site, Oklahoma City
Research Site, Paris
Research Site, Boston
Research Site, Rome
Research Site, Utrecht
Research Site, Barcelona
Research Site, Leeds
Research Site, London
Research Site, Sutton
Lead Sponsor
AstraZeneca
INDUSTRY